跳转至内容
Merck
CN

N3376

烟酰胺

≥98% (HPLC), powder, PARP inhibitor

别名:

吡啶-3-甲酰胺, 烟碱酰胺, 烟酰胺, 维生素 B3, 维生素 PP

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C6H6N2O
化学文摘社编号:
分子量:
122.12
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
202-713-4
MDL number:
Beilstein/REAXYS Number:
383619
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


产品名称

烟酰胺, ≥98% (HPLC), powder

Quality Level

assay

≥98% (HPLC)

form

powder

color

white

mp

128-131 °C (lit.)

application(s)

cell analysis

SMILES string

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI key

DFPAKSUCGFBDDF-UHFFFAOYSA-N

Gene Information

Application

用作某些酶的辅助因子

Biochem/physiol Actions

烟酰胺是维生素B3的酰胺衍生物,是PARP抑制剂

Features and Benefits

该化合物是基因调控研究推荐产品。点击此处 ,查看更多基因调控精选产品。想要了解有关生物活性小分子在其他研究领域应用的更多信息,请访问 sigma.com/discover-bsm

Preparation Note

本品可在室温和干燥条件下密封保存。


Still not finding the right product?

Explore all of our products under 烟酰胺


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2

存储类别

11 - Combustible Solids

flash_point_f

302.0 °F - closed cup

flash_point_c

150 °C - closed cup

ppe

dust mask type N95 (US), Eyeshields, Gloves



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

可生成组织和干细胞来源3D脑、胃肠道、肺和癌症肿瘤类器官模型的类器官培养产品。

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Organoid culture products to generate tissue and stem cell derived 3D brain, intestinal, gut, lung and cancer tumor organoid models.


Stephanie A Campbell et al.
Cell reports, 28(7), 1830-1844 (2019-08-15)
Appropriate regulation of genes that coordinate pancreas progenitor proliferation and differentiation is required for pancreas development. Here, we explore the role of H3K4 methylation and the Trithorax group (TrxG) complexes in mediating gene expression during pancreas development. Disruption of TrxG
Ann-Lii Cheng et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(32), 4067-4075 (2013-10-02)
Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point
Robert J Motzer et al.
The Lancet. Oncology, 14(6), 552-562 (2013-04-20)
In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality



全球贸易项目编号

货号GTIN
N3376-500G04061834115984
N3376-100G04061834115977
N3376-1KG04061826236772